Effect of combined solifenacin and aclatonium in preventing dry mouth in patients with overactive bladder.

about

Effect of combined solifenacin and aclatonium in preventing dry mouth in patients with overactive bladder.

Item

http://www.wikidata.org/entity/Q48261630

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Effect of combined solifenacin ...... ients with overactive bladder.

@en

Effect of combined solifenacin ...... ients with overactive bladder.

@nl

type

Item

label

Effect of combined solifenacin ...... ients with overactive bladder.

@en

Effect of combined solifenacin ...... ients with overactive bladder.

@nl

prefLabel

Effect of combined solifenacin ...... ients with overactive bladder.

@en

Effect of combined solifenacin ...... ients with overactive bladder.

@nl

P1476

Effect of combined solifenacin ...... ients with overactive bladder.

@en

P2093

Dae Yul Yang

http://www.w3.org/2001/XMLSchema#string

Hong Chung

http://www.w3.org/2001/XMLSchema#string

Hyeong Gon Kim

http://www.w3.org/2001/XMLSchema#string

Hyoung Keun Park

http://www.w3.org/2001/XMLSchema#string

Sang-Kuk Yang

http://www.w3.org/2001/XMLSchema#string

Sung Hyun Paick

http://www.w3.org/2001/XMLSchema#string

P2860

Dry mouth - An overview

Stool form scale as a useful guide to intestinal transit time

The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial.

Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada

The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis.

A review of adherence to drug therapy in patients with overactive bladder.

Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review.

Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.

Stimulation of minor salivary glands by intraoral treatment with the cholinesterase inhibitor physostigmine in man.

An overactive bladder symptom and health-related quality of life short-form: validation of the OAB-q SF.

P304

56-60

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/LUTS.12194

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Woo Suk Choi

P577

2017-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28967201

http://www.w3.org/2001/XMLSchema#string